The SURMOUNT-4 study of tirzepatide (brand name Mounjaro for diabetes and Zepbound for obesity) demonstrates the average weight loss with extended use (88 weeks) as well as what happens when the medication is discontinued (weight regain of 67% within 1 year). Anti-obesity medications are long-term, chronic treatments, not cures. Any patient who starts a weight loss medication should plan to remain on it indefinitely, assuming it is working and they are tolerating it.

Breaking down the results of the SURMOUNT-4 study of #tirzepatide #zepbound #obesity #doctor [b6iMSwkyx]

The SURMOUNT-4 study of tirzepatide (brand name Mounjaro for diabetes and Zepbound for obesity) demonstrates the average weight loss with extended use (88 weeks) as well as what happens when the medication is discontinued (weight regain of 67% within 1 year). Anti-obesity medications are long-term, chronic treatments, not cures. Any patient who starts a weight loss medication should plan to remain on it indefinitely, assuming it is working and they are tolerating it.